Mutational or non-mutational activation of the MAPK pathway can activate collateral pathways, including the AKT/mTOR signaling pathway, and is implicated in acquired resistance to targeted inhibition of FLT3, mutant IDH, and BCL2 relevant to AML therapy. Here, BCL2 is linked to acute myeloid leukemia.